Sources

[←1]

^{Kwan, Patrick, and Martin J. Brodie. “Early identification of refractory epilepsy.” New England Journal of Medicine 342.5 (2000): 314-319.}

[←2]

^{Bromfield EB, Cavazos JE, Sirven JI, editors. An Introduction to Epilepsy [Internet]. West Hartford (CT): American Epilepsy Society; 2006. Chapter 3, Neuropharmacology of Antiepileptic Drugs.}

[←3]

^{Wallace, Melisa J., et al. “The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.” Journal of Pharmacology and Experimental Therapeutics 307.1 (2003): 129-137.}

[←4]

^{Deshpande, Laxmikant S., et al. “Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy.” Neuroscience letters 411.1 (2007): 11-16.}

[←5]

^{Ludányi, Anikó, et al. “Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus.” The Journal of neuroscience 28.12 (2008): 2976-2990.}

[←6]

^{Romigi, Andrea, et al. “Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy.” Epilepsia 51.5 (2010): 768-772.}

[←7]

^{Russo, Ethan B. “Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects.” British journal of pharmacology 163.7 (2011): 1344-1364.}

[←8]

^{Mechoulam, R., and E. A. Carlini. “Toward drugs derived from cannabis.” Naturwissenschaften 65.4 (1978): 174-179.}

[←9]

^{Cunha, Jomar M., et al. “Chronic administration of cannabidiol to healthy volunteers and epileptic patients.” Pharmacology 21.3 (1980): 175-185.}

[←10]

^{Ames, F. R., and S. Cridland. “Anticonvulsant effect of cannabidiol.” South African medical journal= Suid-Afrikaanse tydskrif vir geneeskunde 69.1 (1986): 14-14.}

[←11]

^{Trembly, B., and M. Sherman. “Double-blind clinical study of cannabidiol as a secondary anticonvulsant.” Marijuana'90 International Conference on Cannabis and Cannabinoids. Kolympari, Crete, July 8. Vol. 11. 1990.}

[←12]

^{Pelliccia, A., et al. “Treatment with CBD in Oily Solution of Drug-Resistant Paediatric Epilepsies.” Presented at the 2005 Congress on Cannabis and the Cannabinoids, Leiden, The Netherlands: IACM.}

[←13]

^{Porter, Brenda E., and Catherine Jacobson. “Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.” Epilepsy & Behavior 29.3 (2013): 574-577.}

[←14]

^{Gedde, M., and E. Maa. “Whole Cannabis Extract of High Concentration Cannabidiol May Calm Siezures in Highly Refractory Pediatric Epilepsies.” In Press with the American Epilepsy Society, 67th Annual Meeting, December 2013.}

[←15]

^{Blair RE, Deshpande LS, DeLorenzo RJ. Cannabinoids: is there a potential treatment role in epilepsy? Expert opinion on pharmacotherapy. 2015;16(13):1911-1914.}

[←16]

^{Hussain, Shaun A., et al. “Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox–Gastaut syndrome.” Epilepsy & Behavior (2015).}

[←17]

^{Vezzani, Annamaria, et al. “The role of inflammation in epilepsy.” Nature Reviews Neurology 7.1 (2011): 31-40.}

[←18]

^{Vezzani, Annamaria, and Tallie Z. Baram. “New Roles for Interleukin‐1 Beta in the Mechanisms of Epilepsy.” Epilepsy currents 7.2 (2007): 45-50.}

[←19]

^{Russo, Ethan B.}

[←20]

^{Drysdale, Alison J., et al. “Cannabidiol-induced intracellular Ca 2+ elevations in hippocampal cells.” Neuropharmacology 50.5 (2006): 621-631.}

[←21]

^{Mechoulam, R., and E. Shohami. “Endocannabinoids and traumatic brain injury.” Molecular neurobiology 36.1 (2007): 68-74.}

[←22]

^{Ryan, Duncan, et al. “Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels.” The Journal of Neuroscience 29.7 (2009): 2053-2063.}

[←23]

^{Esposito, Giuseppe, et al. “Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR involvement.” (2011): e28668.}

[←24]

^{Campos, Alline C., et al. “The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.” International Journal of Neuropsychopharmacology 16.6 (2013): 1407-1419.}

[←25]

^{Friedman, D., M. R. Cilio, and N. Tilton. “The effect of Epidiolex (Cannabidiol) on serum levels of concomminant anti-epileptic drugs in children and young adults with treatment-resistant epilepsy in an expanded access program.” American Epilepsy Society, Seattle, WA (2014).}

[←26]

^{Nóbrega de Almeida, Reinaldo, et al. “Essential oils and their constituents: anticonvulsant activity.” Molecules 16.3 (2011): 2726-2742.}